Ocular Therapeutix (NASDAQ:OCUL) Earning Somewhat Positive News Coverage, Analysis Finds

Ausiliatrice Cristiano
Agosto 10, 2017

OCUL's SI was 5.91M shares in August as released by FINRA. Its down 3.68% from 6.13 million shares previously. With 645,200 avg volume, 9 days are for Ocular Therapeutix Incorporated (NASDAQ:OCUL)'s short sellers to cover OCUL's short positions. The SI to Ocular Therapeutix Incorporated's float is 25.99%. The stock increased 0.37% or $0.28 during the last trading session, reaching $76.69.

Shares of Ocular Therapeutix (NASDAQ OCUL) traded up 9.38% during trading on Friday, hitting $5.77. It has underperformed by 26.20% the S&P500.

Montrusco Bolton Investments Inc increased Ca Inc (CA) stake by 313.84% reported in 2016Q4 SEC filing. 499,150 shares of the company's stock were exchanged. Columbus Circle Investors now owns 1,087,605 shares of the biopharmaceutical company's stock worth $10,093,000 after buying an additional 617,515 shares in the last quarter. Ca Inc now has $13.47 billion valuation. The stock increased 9.38% or $0.49 on August 4, reaching $5.77. (NASDAQ:CA) has risen 0.22% since August 7, 2016 and is uptrending. Ocular Therapeutix, Inc. has 0 buy ratings, 2 holds and 0 sells even after the stock tumbled -51.54% from its high of $11.91 to a $153.08 million market value through last close. Therefore 71% are positive. Alps Advisors Inc. boosted its stake in Ocular Therapeutix by 5.9% in the second quarter. They issued a "buy" rating and a $10.00 price objective on the stock. Morgan Stanley downgraded shares of Ocular Therapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a report on Friday, June 23rd. Analysts forecast that Ocular Therapeutix will post ($2.19) earnings per share for the current year. Cowen and Company restated an outperform rating and set a $60.00 price target on shares of Ocular Therapeutix in a report on Monday, March 13th. The company was downgraded on Friday, June 23 by Morgan Stanley. The rating was maintained by H.C. Wainwright on Wednesday, August 2 with "Buy". The firm has "Overweight" rating by Morgan Stanley given on Thursday, February 18. The company was maintained on Thursday, April 28 by Morgan Stanley.

Morgan Stanley reiterated their equal weight rating on shares of Ocular Therapeutix, Inc. The company's market cap is $167.49 million. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. It now has negative earnings. The Company's bioresorbable hydrogel based product candidates are created to provide sustained delivery of therapeutic agents to the eye. Zacks Investment Research raised shares of Ocular Therapeutix from a "hold" rating to a "buy" rating and set a $11.00 price objective for the company in a report on Tuesday, May 16th.

Investors sentiment decreased to 0.7 in Q4 2016. Its down 0.15, from 0.85 in 2016Q3. It fall, as 64 investors sold GGP shares while 121 reduced holdings. 37 funds opened positions while 134 raised stakes. 742.41 million shares or 7.29% less from 800.79 million shares in 2016Q3 were reported. Exane Derivatives owns 3,168 shares. The biggest holder now is Dr. Amarpreet Sawhney, PhD who owns 632,090 shares (2.18% of those outstanding), whilst Mr. James Fortune holds 112,060 (0.39% of shares outstanding) and Mr. Eric Ankerud holds 78,651 (0.27% of shares outstanding). Axa invested in 0.04% or 343,812 shares. Fmr Lc accumulated 119,299 shares. Telsey Advisory Group maintained the shares of DG in report on Friday, December 2 with "Market Perform" rating. Bluemountain Capital Ltd Limited Liability Company holds 0.01% in CA, Inc. (NASDAQ:CA) or 21,900 shares. Guardian Life Of America reported 0.01% stake. Moreover, Old National Retail Bank In has 0.11% invested in CA, Inc. (NASDAQ:CA) for 59,802 shares. Moreover, Ibm Retirement Fund has 0.03% invested in CA, Inc. Next Fincl Gp reported 0% of its portfolio in CA, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre relazioni OverNewsmagazine

Discuti questo articolo